

**Table SI. Dermatology Life Quality Index (DLQI) scores reported by patients with psoriasis treated with ixekizumab (IXE) or ustekinumab (UST) for 52 weeks**

| DLQI components        | Baseline<br>Mean (SD) | Week 12<br>Mean (SD) | Week 52<br>Mean (SD) |
|------------------------|-----------------------|----------------------|----------------------|
| Daily activities       |                       |                      |                      |
| UST                    | 2.3 (1.8)             | -1.63 (1.8)          | -1.79 (1.7)          |
| IXE                    | 2.2 (1.9)             | -1.97 (1.7)          | -1.96 (1.8)          |
| Leisure                |                       |                      |                      |
| UST                    | 2.0 (2.0)             | -1.45 (1.8)          | -1.69 (1.8)          |
| IXE                    | 1.9 (2.0)             | -1.44 (1.8)          | -1.51 (1.8)          |
| Personal relationships |                       |                      |                      |
| UST                    | 1.9 (1.9)             | -1.32 (1.7)          | -1.58 (1.7)          |
| IXE                    | 1.5 (1.8)             | -1.17 (1.7)          | -1.26 (1.7)*         |
| Symptoms and feelings  |                       |                      |                      |
| UST                    | 3.8 (1.6)             | -2.53 (1.7)          | -2.64 (1.7)          |
| IXE                    | 3.8 (1.6)             | -2.93 (1.7)          | -2.86 (1.9)          |
| Treatment              |                       |                      |                      |
| UST                    | 1.2 (1.2)             | -0.87 (1.1)          | -0.92 (1.1)          |
| IXE                    | 0.9 (1.0)             | -0.77 (1.1)          | -0.85 (1.1)          |

\* $p < 0.05$  vs UST by Wilcoxon rank sum test. SD: standard deviation.